Childhood Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, February 2012, Pages: 75

Childhood Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Childhood Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Childhood Epilepsy Therapeutics market. The report identifies the key trends shaping and driving the global Childhood Epilepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Childhood Epilepsy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Childhood Epilepsy Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Childhood Epilepsy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Childhood Epilepsy Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Childhood Epilepsy Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Childhood Epilepsy Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Childhood Epilepsy Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Childhood Epilepsy Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Childhood Epilepsy Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Childhood Epilepsy Therapeutics - Introduction
2.1 Overview
2.1.1 Types of Epilepsy
2.1.2 Childhood Epilepsy Syndromes
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.3.1 The US
2.3.2 EU
2.3.3 Japan
2.3.4 Health Related Quality of Life (HRQoL)
2.4 Symptoms
2.5 Diagnosis
2.5.1 Tests
2.6 Treatment and Management Pattern
2.6.1 Pharmacological Treatment
2.6.2 Ketogenic Diet
2.6.3 Epilepsy Surgery
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 Childhood Epilepsy Therapeutics - Market Characterization
3.1 Overview
3.2 Childhood Epilepsy Therapeutics Market Size (2006-2011) - Global
3.3 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Global
3.4 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - The US
3.5 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - The US
3.6 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - France
3.7 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - France
3.8 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - Germany
3.9 Childhood Epilepsy Therapeutics Market Forecast (2011-2019) - Germany
3.10 Childhood Epilepsy Therapeutics Market Size (2006-2011) - Italy
3.11 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Italy
3.12 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - Spain
3.13 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Spain
3.14 Childhood Epilepsy Therapeutics Market Size (2006-2011) - The UK
3.15 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - The UK
3.16 Childhood Epilepsy Therapeutics Market Size (2006-2011) - Japan
3.17 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Japan
3.18 Drivers and Barriers
3.18.1 Drivers for Childhood Epilepsy Therapeutics Market
3.18.2 Barriers for the Childhood Epilepsy Therapeutics Market
3.19 Opportunity and Unmet Needs
3.20 Key Takeaway
4 Childhood Epilepsy Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Childhood Epilepsy Disorders Therapeutics market
4.3.1 Lamictal (lamotrigine)
4.3.2 Topamax (topiramate)
4.3.3 Sabril (vigabatrin)
4.3.4 Keppra (levetiracetam)
4.3.5 Trileptal (oxcarbazepine)
4.3.6 Key Takeaway
5 Childhood Epilepsy Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pipeline by Phases of Development
5.3.1 Childhood Epilepsy Therapeutics - Filed Pipeline
5.3.2 Childhood Epilepsy Therapeutics - Phase III Pipeline
5.3.3 Childhood Epilepsy Therapeutics - Phase II/III Pipeline
5.3.4 Childhood Epilepsy Therapeutics - Phase II Pipeline
5.3.5 Childhood Epilepsy Therapeutics-Phase I Pipeline
5.4 Childhood Epilepsy Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Promising Drugs under Clinical Development
5.7 Profile for Promising Drugs
5.7.1 SPN-538
5.7.2 Brivaracetam
5.8 Key Takeaway
6 Childhood Epilepsy Therapeutics:Clinical Trials Mapping
6.1 Overview
6.2 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.3 Clinical Trials by Phase
6.4 Clinical Trials by Trial Status
6.5 Prominent Sponsors
6.6 Top Companies Participating in Therapeutics Clinical Trials
7 Childhood Epilepsy Therapeutics:Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Childhood Epilepsy Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 UCB S.A.
8.2.2 Supernus Pharmaceuticals
8.2.3 Eisai Co., Ltd.
8.2.4 Kirin Holdings Company, Limited
8.2.5 GlaxoSmithKline plc
8.2.6 Pfizer
8.2.7 Bial Portela C.S.A.
9 Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

1.1 List of Tables
Table 1: AED options by Seizure Types
Table 2: AED Options by Childhood Epilepsy Syndromes
Table 3: Childhood Epilepsy Therapeutics Market, Global, Revenue($m), 2006-2011
Table 4: Childhood Epilepsy Therapeutics Market, Global, Forecast, ($m), 2011 - 2019
Table 5: Childhood Epilepsy Therapeutics Market, The US, Revenue ($m), 2006 - 2011
Table 6: Childhood Epilepsy Therapeutics Market, The US, Forecast ($m), 2011 - 2019
Table 7: Childhood Epilepsy Therapeutics Market, France, Revenue($m), 2006 - 2011
Table 8: Childhood Epilepsy Therapeutics Market, France, Forecast ($m), 2011 - 2019
Table 9: Childhood Epilepsy Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Table 10: Childhood Epilepsy Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Table 11: Childhood Epilepsy Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Table 12: Childhood Epilepsy Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Table 13: Childhood Epilepsy Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Table 14: Childhood Epilepsy Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 15: Childhood Epilepsy Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 16: Childhood Epilepsy Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 17: Childhood Epilepsy Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 18: Childhood Epilepsy Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 19: Efficacy Results in Double-Blind, Placebo-Controlled, Add-On Epilepsy Trials
Table 20: Spasm Freedom by Primary Criteria
Table 21: Reduction in Mean Over Placebo in Weekly Frequency of Partial Onset Seizures
Table 22: Summary of Percentage Change in Partial Seizure Frequency from Baseline for Placebo-Controlled Adjunctive Therapy Trials
Table 23: Childhood Epilepsy Therapeutics, Regulatory Filed Pipeline, 2011
Table 24: Childhood Epilepsy Therapeutics, Phase III Pipeline, 2011
Table 25: Childhood Epilepsy Therapeutics, Phase II/III Pipeline, 2011
Table 26: Childhood Epilepsy Therapeutics, Phase II Pipeline, 2011
Table 27: Childhood Epilepsy Therapeutics, Phase I Pipeline, 2011
Table 28: Childhood Epilepsy Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 29: Childhood Epilepsy Therapeutics Market, Number of Clinical Trials by Region, 2011
Table 30: Childhood Epilepsy Therapeutics Market, Number of Clinical Trials by Phase of Development, 2011
Table 31: Childhood Epilepsy Therapeutics Market, Global, Number of Clinical Trials by Trial Status, 2011
Table 32: Childhood Epilepsy Therapeutics Market, Global, Number of Clinical Trials by Prominent Sponsors, 2011
Table 33: Childhood Epilepsy Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Table 34: UCB, CNS Pipeline, 2011
Table 35: UCB, Epilepsy Pipeline, 2011
Table 36: Supernus Pharmaceuticals, Inc., CNS Pipeline, 2011
Table 37: Supernus Pharmaceuticals, Inc., Epilepsy Pipeline, 2011
Table 38: Eisai Co., Ltd., CNS Pipeline, 2011
Table 39: Eisai Co., Ltd., Epilepsy Pipeline, 2011
Table 40: Kyowa Hakko Kirin Co., Ltd, CNS Pipeline, 2011
Table 41: Kyowa Hakko Kirin Co., Ltd, Epilepsy Pipeline, 2011
Table 42: GSK, CNS Pipeline, 2011
Table 43: GSK, Epilepsy Pipeline, 2011
Table 44: Pfizer, CNS Pipeline, 2011
Table 45: Pfizer, Childhood Epilepsy Pipeline, 2011
Table 46: Bial-Portela C S.A., CNS Pipeline, 2011
Table 47: Bial-Portela C S.A., Pipeline for Childhood Epilepsy, 2011

1.2 List of Figures
Figure 1: Referral Pathway for Childhood Epilepsy Disorders
Figure 2: Childhood Epilepsy Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Figure 3: Childhood Epilepsy Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 4: Childhood Epilepsy Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 5: Childhood Epilepsy Therapeutics Market, The US, Forecast ($m), 2011 - 2019
Figure 6: Childhood Epilepsy Therapeutics Market, France, Revenue($m), 2006 - 2011
Figure 7: Childhood Epilepsy Therapeutics Market, France, Forecast ($m), 2011 - 2019
Figure 8: Childhood Epilepsy Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Figure 9: Childhood Epilepsy Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Figure 10: Childhood Epilepsy Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Figure 11: Childhood Epilepsy Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Figure 12: Childhood Epilepsy Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Figure 13: Childhood Epilepsy Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 14: Childhood Epilepsy Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 15: Childhood Epilepsy Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 16: Childhood Epilepsy Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 17: Childhood Epilepsy Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 18: Opportunity and Unmet Need in the Childhood Epilepsy Therapeutics Market, 2011
Figure 19: Strategic Competitor Assessment of the Major Marketed Products in Childhood Epilepsy, 2011
Figure 20: Childhood Epilepsy Therapeutics Pipeline by Phase of Clinical Development (%), 2011
Figure 21: Childhood Epilepsy Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011
Figure 22: Technology Trends Analytic Framework of the Childhood Epilepsy Therapeutics Pipeline, 2011
Figure 23: Technology Trends Analytic Framework of the Childhood Epilepsy Therapeutics Pipeline - Description, 2011
Figure 24: Childhood Epilepsy Therapeutics Market, Number of Clinical Trials by Region, 2011
Figure 25: Childhood Epilepsy Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011
Figure 26: Childhood Epilepsy Therapeutics Market, Global, Clinical Trials by Trial Status (%), 2011
Figure 27: Childhood Epilepsy Therapeutics Market, Global, Clinical Trials by Overall Sponsors (%), 2011
Figure 28: Childhood Epilepsy Therapeutics Market, Global, Clinical Trials by Prominent Sponsors (%), 2011
Figure 29: Childhood Epilepsy Therapeutics Market, Global, Number of Clinical Trials by Top Companies, 2011
Figure 30: Key Events Competition in the Childhood Epilepsy Therapeutics, 2011
Figure 31: Implications for Future Market Competition in the Childhood Epilepsy, 2011
Figure 32: Childhood Epilepsy Therapeutics Market, Clinical Pipeline by Company, 2011
Figure 33: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Childhood Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. - an essential source of information and analysis on the global childhood epilepsy market. The report identifies the key trends shaping and driving the global childhood epilepsy market and provides insights into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global childhood epilepsy sector. The analysis is constructred using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

Childhood Epilepsy Therapeutics Market is Forecast to Show Steady Growth until 2019

GlobalData estimates the global childhood epilepsy therapeutics market was worth $722m in 2011, and is forecast to register slow growth at a Compound Annual Growth Rate (CAGR) of 5.0% to reach $1,065m by 2019. The slow growth during the forecast period may be attributed to the patent expiry of second-generation antiepileptic drugs (AEDs) such as Keppra (levetiracetam), Lamictal (lamotrigine) and Topamax (topiramate). The decline in the market is due to competition from the generics that are likely to capture a greater market share during the forecast period. The launch of SPN-538 and Brivaracetam are expected to sustain positive growth through 2019. SPN-538 is an analogue of Topiramate and Brivaracetam is a new compound developed by UCB. The drug has a molecular structure similar to that of Keppra.

Decline in Market Size Due to Patent Expiries is Expected to be Fulfilled by the Launch of Pipeline Molecules

GlobalData’s research indicates that the market for childhood epilepsy therapeutics is well served by the current approved drugs such as Keppra, Lamictal and Topamax. The childhood epilepsy therapeutics market will face the patent expiry of leading drugs such as Keppra (US and EU), Lamictal (US) and Topamax (US and EU). However, the expected launch of SPN-538 by Supernus Pharmaceuticals and Brivaracetam by UCB S.A. will help to maintain the positive growth trend during the forecast period.

Current Treatment Options are Moderately Successful in Meeting Market Demand

GlobalData’s research indicates that the current competition in the market is strong. The market is well served by the approved and off-label products. The products in the market successfully meet the needs of physicians as well as patients. However, 25% of children still remain refractory to medical therapies.

UCB S.A.
Supernus Pharmaceuticals
Eisai Co., Ltd.
Kirin Holdings Company, Limited
GlaxoSmithKline plc
Pfizer
Bial Portela C.S.A.

Customers who bought this item also bought

• Global Epilepsy Drug Pipeline Capsule - 2012
• Medical Nutrition - A Global Market Overview
• Epilepsy (Event Driven)
• Diabetes Diagnostics - Global Strategic Business Report
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• Disinfectants - Global Strategic Business Report
• Stakeholder Insight: Epilepsy - Neurologists remain loyal to brands in genericized market
• Molecular Diagnostics - Global Strategic Business Report
• Epilepsy: An Atlas of Investigation and Management
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report